Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab + Pola-R-CHP vs Pola-R-CHP in previously untreated large B-cell lymphoma
jRCT2051230190Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of glofitamab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Started Apr 2024; status: active, not recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2051230190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230190.